ASBrS Endorses Cryoablation for Low-Risk Breast Cancer, Boosting IceCure's ProSense
Event summary
- ASBrS updated its 2026 Resource Guide to recommend cryoablation for selected low-risk breast cancer patients.
- IceCure's ProSense® system received FDA clearance in October 2025 for low-risk breast cancer treatment.
- The ASBrS guide highlights cryoablation's minimally invasive nature and cosmetic benefits.
- ProSense® targets a U.S. patient population of approximately 200,000 women annually.
The big picture
The ASBrS endorsement of cryoablation aligns with broader trends in breast cancer treatment toward minimally invasive, patient-centric approaches. IceCure's ProSense® system is positioned to capitalize on this shift, particularly for older patients with low-risk tumors. The endorsement comes after FDA clearance, signaling growing regulatory and clinical acceptance of cryoablation as a standard treatment option.
What we're watching
- Adoption Pace
- How quickly physicians and patients will embrace cryoablation as a viable alternative to surgery.
- Reimbursement Dynamics
- Whether the established CPT III reimbursement code will sustain commercial adoption momentum.
- Competitive Landscape
- The pace at which other cryoablation technologies may emerge to challenge ProSense®'s market position.
Related topics